Published in:
Open Access
01-01-2021 | Ticagrelor | Journal Club
The role of ticagrelor in acute ischaemic stroke and high-risk TIA management
Authors:
Claire MacIver, Tom Hughes
Published in:
Journal of Neurology
|
Issue 1/2021
Login to get access
Excerpt
Following a transient ischaemic attack (TIA) or cerebral infarction associated with mild disability (NIHSS ≤ 5), the risk of recurrence is high in the subsequent 30 days, highlighting the importance of early interventions. Current regimens support the use of one antiplatelet agent in infarction with severe disability, typically Aspirin (a prostaglandin H synthase in inhibitor) 300 mg daily for 2 weeks, followed by Clopidogrel (which inhibits the binding of adenosine diphosphate to its platelet P2Y12 receptor) 75 mg daily. For patients with high-risk TIAs or cerebral infarction with mild disability (NIHSS score of five or less), dual-antiplatelet therapy for 10–21 days (depending on bleeding risk) with aspirin 75 mg and clopidogrel 75 mg is recommended, followed by clopidogrel 75 mg alone. …